At The Leukemia & Lymphoma Society of Canada (LLSC) we're committed to funding research to help cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
When LLSC was founded in 1955, a diagnosis of leukemia, lymphoma, Hodgkin's disease or myeloma was almost always fatal. Today, thanks to innovative research funded in part by LLSC, survival rates for some blood cancers have doubled--and some have even tripled.
In 2015, LLSC invested over $2.7 million in innovative, life-changing research to accelerate new cancer treatments, therapies, and cures.
The Leukemia & Lymphoma Society of Canada (LLSC) and The Leukemia & Lymphoma Society in the US (LLS) fund research across the continuum, from basic research through clinical trials, from bench to bedside. To date, we have invested more than $1 billion in research to advance therapies and save lives. Research grants have funded many of today's most promising advances, including targeted therapies and immunotherapies and some of the therapies first approved for blood cancer patients are now helping patients with other types of cancers and other serious diseases.